663 related articles for article (PubMed ID: 22947595)
21. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
22. [Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
Lombard-Bohas C; Cariou B; Vergès B; Coriat R; N'guyen T; François E; Hammel P; Niccoli P; Hentic O
Bull Cancer; 2014 Feb; 101(2):175-83. PubMed ID: 24557872
[TBL] [Abstract][Full Text] [Related]
23. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
24. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
Gabardi S; Baroletti SA
Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
[TBL] [Abstract][Full Text] [Related]
25. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
26. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
27. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.
Ito T; Okusaka T; Ikeda M; Igarashi H; Morizane C; Nakachi K; Tajima T; Kasuga A; Fujita Y; Furuse J
Jpn J Clin Oncol; 2012 Oct; 42(10):903-11. PubMed ID: 22859827
[TBL] [Abstract][Full Text] [Related]
28. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
29. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
Khagi S; Saif MW
Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
[TBL] [Abstract][Full Text] [Related]
31. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
Shameem R; Hamid MS; Wu S
Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
[TBL] [Abstract][Full Text] [Related]
32. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.
Yao J; Wang JY; Liu Y; Wang B; Li YX; Zhang R; Wang LS; Liu L
Med Oncol; 2014 Dec; 31(12):251. PubMed ID: 25395378
[TBL] [Abstract][Full Text] [Related]
34. Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective.
Phan AT
Cancer Treat Rev; 2013 Feb; 39(1):3-9. PubMed ID: 22459199
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
37. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2018; 211():101-123. PubMed ID: 30069763
[TBL] [Abstract][Full Text] [Related]
38. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
Wiedenmann B; Pavel M; Kos-Kudla B
Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
[TBL] [Abstract][Full Text] [Related]
39. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Djukom C; Porro LJ; Mrazek A; Townsend CM; Hellmich MR; Chao C
Pancreas; 2014 Jan; 43(1):88-92. PubMed ID: 24263107
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
